A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Last updated: November 26, 2025
Sponsor: University Health Network, Toronto
Overall Status: Active - Not Recruiting

Phase

1

Condition

Acute Myeloid Leukemia

Platelet Disorders

Leukemia

Treatment

IL-12

Clinical Study ID

NCT02483312
DDP-IL-12
OZM-068
  • Ages > 18
  • All Genders

Study Summary

This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with AML and >=18 years of age.

  • Agrees to participate in the study and signs the informed consent

  • Viable cells are available for successful modification

  • First or higher complete remission and have high risk features of relapse.

  • Patients who have received prior treatment and are not in remission must have stablewhite blood cell count and are not receiving any chemotherapy or desiring furtherintensive treatment.

  • Less than 10% blast cells in the bone marrow following induction or re-inductiontherapy and not desiring further intensive treatment.

  • Acceptable creatinine, Aspartate transaminase (AST), Alkaline phosphatase (ALP),bilirubin lab results.

  • Agree to use contraception

  • Not pregnant

  • Able to comply with study procedures

Exclusion

Exclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status >2

  • Known persistent infection

  • Known central nervous system (CNS) disease

  • Greater than 10% blasts in the bone marrow or circulating blast cells

  • Life expectancy < 2 months

  • Receiving any chemotherapy, corticosteroids, Cox2 inhibitors or any non-drugtherapies with the intent of altering the immune response or kill leukemic cellswithin one week prior to infusion of IL-12, except azacytidine.

  • Patients who are HIV positive.

Study Design

Total Participants: 9
Treatment Group(s): 1
Primary Treatment: IL-12
Phase: 1
Study Start date:
September 01, 2015
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • Princess Margaret Centre Centre

    Toronto, Ontario M5G 2M9
    Canada

    Site Not Available

  • Princess Margaret Centre Centre

    Toronto 6167865, Ontario 6093943 M5G 2M9
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.